埃万妥单抗联合方案为EGFR突变晚期NSCLC伴肝转移患者带来治疗新选择。

*以下内容仅供医疗卫生专业人士浏览。

打开网易新闻 查看精彩图片
打开网易新闻 查看精彩图片

参考文献：

[1]Gen S, et al. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis. BMC Cancer. 2022 Jun 14;22(1):654.

[2]张婵媛, 等. 埃万妥单抗联合lazertinib开启EGFR突变晚期NSCLC治疗新格局[J].循证医学, 2025, 25(1):27-30.

[3]Riihimäki M, et al. Metastatic sites and survival in lung cancer. Lung Cancer. 2014 Oct;86(1):78-84.

[4]Felip E, et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Ann Oncol. 2024 Sep;35(9):805-816.

[5]Yang JC, et al. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025 Sep 7. Supplementary Appendix.

[6]陈敏, 等. 非小细胞肺癌治疗药物——埃万妥单抗[J].临床药物治疗杂志, 2023.

[7]Moores SL, et al. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. Cancer Res. 2016 Jul 1;76(13):3942-53.

审批编码：CP-553628

批准分发日期：2025/11/25

有效期：2026/11/25

*“医学界”力求所发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。